Corbus Pharmaceuticals Holdings, Inc.
CRBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595097
In the last 90 days, Corbus Pharmaceuticals Holdings, Inc. insiders filed 1 open-market purchase and 3 sales; 107 institutions reported holding it in 13F filings for Q2 2026, worth $129.1M in total; no superinvestor holds it.
13F holders, Q1 2026
Institutional positions in Corbus Pharmaceuticals Holdings, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 108
- +11 vs. Q4 2025
- Shares held
- 12.9M
- +659.1K (+5.4%) vs. Q4 2025
- Total value
- $121.2M
- +$21.5M (+21.6%) vs. Q4 2025
- New holders
- 24
- 33 more added
- Sold out
- 13
- 22 more reduced
4 institutions that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRBP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 107 | $129.1M |
| Q1 2026 | 108 | $121.2M |
| Q4 2025 | 101 | $108.4M |
| Q3 2025 | 81 | $111.5M |
| Q2 2025 | 80 | $62.5M |
| Q1 2025 | 86 | $55.4M |
| Q4 2024 | 99 | $129.3M |
| Q3 2024 | 107 | $243.1M |
| Q2 2024 | 107 | $486.1M |
| Q1 2024 | 82 | $334.7M |
| Q4 2023 | 34 | $4.53M |
| Q3 2023 | 27 | $5.01M |
| Q2 2023 | 28 | $5.80M |
| Q1 2023 | 30 | $5.26M |
| Q4 2022 | 63 | $1.31M |
| Q3 2022 | 65 | $3.86M |
| Q2 2022 | 71 | $8.04M |
| Q1 2022 | 73 | $19.7M |
| Q4 2021 | 83 | $27.2M |
| Q3 2021 | 87 | $45.6M |
| Q2 2021 | 99 | $91.0M |
| Q1 2021 | 107 | $86.2M |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Corbus Pharmaceuticals Holdings, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 383,462 | $3.60M | 3.17% | −6,454−1.7% | Reduced |
| Diadema Partners LP | 439,957 | $4.13M | 1.71% | +439,957 | New |
| Prosight Management, LP | 697,108 | $6.55M | 1.07% | +13,236+1.9% | Added |
| Citadel Advisors LLC | 727,060 | $6.83M | 0.00% | −116,133−13.8% | Reduced |
| Vanguard Capital Management LLC | 734,106 | $6.89M | 0.00% | +734,106 | New |
| Standard Life Aberdeen plc | 1,321,750 | $12.4M | 0.02% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 1,737,287 | $16.3M | 0.37% | +140,000+8.8% | Added |
| Cormorant Asset Management, LP | 2,344,971 | $22.0M | 1.11% | 00.0% | Unchanged |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −955,000−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −135,730−100.0% | Sold out |
| HealthInvest Partners AB | 0 | $0 | 0.00% | −107,255−100.0% | Sold out |
| B. Riley Financial, Inc. | 0 | $0 | 0.00% | −38,714−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −27,275−100.0% | Sold out |
| Quest Partners LLC | 0 | $0 | 0.00% | −22,906−100.0% | Sold out |
| Walleye Trading LLC | 0 | $0 | 0.00% | −15,851−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −12,480−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −11,056−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −10,760−100.0% | Sold out |
| Avanza Fonder AB | 0 | $0 | 0.00% | −4,868−100.0% | Sold out |
| Optiver Holding B.V. | 0 | $0 | 0.00% | −929−100.0% | Sold out |
| Flagship Harbor Advisors, LLC | 0 | $0 | 0.00% | −16−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |
| Comerica Bank | – | – | – | – | Not filed |
| Sherbrooke Park Advisers LLC | – | – | – | – | Not filed |
| ORG Partners LLC | – | – | – | – | Not filed |